Drugs / Plasma rich in growth factors

Trials 4 · a red edge is where a trial was stopped

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT06115005 Jun 2022 → Dec 2023 macular holes Minia University Unknown No outcome recorded
Phase 32 trials
Phase 3 NCT01915979 Feb 2014 → May 2015 rotator cuff syndrome Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias Completed No outcome recorded
Phase 3 NCT02039531 Aug 2011 → Feb 2013 osteoarthritis, knee Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias Completed No outcome recorded
Phase 41 trial
Phase 4 NCT06952998 Nov 2025 → May 2026 overdue ulcer of lower limbs Biotechnology Institute IMASD Recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT05595772 Comparator Feb 2022 → Jul 2023 Minia University Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Plasma rich in growth factors Plasma rich in growth factors (PRGF), a subtype of P-PRP (pure platelet-rich plasma), is a supernatant enriched in plasma and platelet-derived morphogens, proteins, and growth factors.” NCT05595772
4

NCT02039531

NCT06952998

NCT06115005

NCT01915979

Known as PRGF “Plasma rich in growth factors (PRGF), a subtype of P-PRP (pure platelet-rich plasma), is a supernatant enriched in plasma and platelet-derived morphogens, proteins, and growth factors.” NCT05595772
3

“Topical application of Plasma Rich in Growth Factors (PRGF)” NCT06952998

“Biological: Plasma rich in growth factors (PRGF)” NCT01915979

“Plasma rich in growth factors ( PRGF )” NCT06115005

Modality Other / unclassified “PRGF, a subtype of P-PRP (pure platelet-rich plasma)” NCT05595772
Route Other “This group will receive a total of three intraarticular injections of 6-8 ml.” NCT01915979